Web Results
Find Health Information on Healthline
Find Info About:
Healthline is the leading provider of health information.

www.scotusblog.com/case-files/cases/united-states-ex-rel-noah-nathan-v-takeda-pharmaceuticals-inc-north-america-inc

Mar 31, 2014 ... May 28 2013, Order extending time to file response to petition to and including July 12, 2013. Jul 12 2013, Brief of respondents Takeda Pharmaceuticals North America, Inc., et al. in opposition filed. Jul 30 2013, Reply of petitioner U. S. ex rel . Noah Nathan filed. Jul 31 2013, DISTRIBUTED for Conference of ...

dockets.justia.com/docket/new-jersey/njdce/2:2018cv00297/364138

Jan 9, 2018 ... COMBS et al v. TAKEDA PHARMACEUTICAL COMPANY LIMITED et al. Plaintiff: CAREN COMBS and ROBERT COMBS. Defendant: TAKEDA PHARMACEUTICAL COMPANY LIMITED, TAKEDA PHARMACEUTICALS U.S.A. , INC., TAKEDA PHARMACEUTICALS, LLC, TAKEDA PHARMACEUTICALS ...

www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2014/04/08/jury-awards-9b-in-1st-mdl-actos-bladder-cancer-trial-against-takeda-eli-lilly.aspx

Apr 8, 2014 ... Inc., according to Takeda (In Re: Actos [Pioglitazone] Products Liability Litigation, MDL Docket No. 2299, No. 6:11-md-2299, Allen v. Takeda Pharmaceuticals North America Inc., et al., No. 12-64, E.D. La.). According to an April 8 press release issued by Takeda, the nine-member jury in the U.S. District ...

www.law360.com/articles/652395/fed-circ-oks-hikma-gout-drug-sales-in-takeda-ip-case

May 6, 2015 ... In a 2-1 decision, the appeals court affirmed a Delaware federal judge's ruling denying Takeda's motion for a preliminary injunction on Hikma, holding there is not sufficient evidence that ... West-Ward Pharmaceutical Corp. et al., case number 2015-1139, in the U.S. Court of Appeals for the Federal Circuit.

www.cafc.uscourts.gov/sites/default/files/opinions-orders/15-2066.Opinion.7-13-2017.1.PDF

Jul 17, 2017 ... NEWMAN, Circuit Judge. Millennium Pharmaceuticals, Inc. is the exclusive li- censee of U.S. Patent No. 6,713,446 (“the '446 Patent”), issued March 30, 2004 and assigned to the United States. Millennium developed the patented product for treatment of oncology disease, particularly multiple myeloma and.